Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin

Translational Oncology(2021)10.1016/j.tranon.2021.101059Source: DataRank Database

IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin is a research paper published in Translational Oncology (2021). On theSindex it has a DataRank of 0. It has been cited 37 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access37 citations

Download PDF

Cite:

Linked data & code

gen doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 4.69)OA: goldTopics (24)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Jun Xu ORCID,Qiang Du ORCID,Yihe Yan ORCID,David A. Geller ORCID,Yarong Guo ORCID

Live enrichment

PubMed:33735820 PMC:PMC7988337 OpenAlex:https://openalex.org/W3137148695

National Institutes of Health

Grant: 1P30DK120531-01

Pittsburgh Liver Research Center

NIH

FWCI

4.69

Citation Percentile

1.0%

Influential Citations

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.sciencedirect.com/science/article/pii/S1936523321000516/pdf

GOLDhttps://doi.org/10.1016/j.tranon.2021.101059

publisherhttps://www.sciencedirect.com/science/article/pii/S1936523321000516/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1936523321000516?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1936523321000516?httpAccept=text/plain

Fields of Study

Cancer Mechanisms and TherapyCancer-related gene regulationUbiquitin and proteasome pathwaysMedicineBiology0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

LenvatinibCancer researchMedicineHepatocellular carcinomaOncologyApoptosisInternal medicineBiologySorafenibcellular apoptosisΒ-cateninInterferon Regulatory Factor 2 (Irf2)Lenvatinib-resistanceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282Original Research

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin

FAIR Checklist

Authors (5)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)